购物车
- 全部删除
- 您的购物车当前为空
Linzagolix 是一种口服有活性的非多肽GnRH 拮抗剂。可用于研究子宫肌瘤、子宫腺肌症、子宫内膜异位症。
Linzagolix 是一种口服有活性的非多肽GnRH 拮抗剂。可用于研究子宫肌瘤、子宫腺肌症、子宫内膜异位症。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 388 | 现货 | |
5 mg | ¥ 859 | 现货 | |
10 mg | ¥ 1,320 | 现货 | |
25 mg | ¥ 2,980 | 现货 | |
50 mg | ¥ 4,630 | 现货 | |
100 mg | ¥ 6,490 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 963 | 现货 |
产品描述 | Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis. |
分子量 | 508.42 |
分子式 | C22H15F3N2O7S |
CAS No. | 935283-04-8 |
Smiles | COc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 55 mg/ml (108.18 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容